Advertisement

Melanoma pp 525-531 | Cite as

Chemotherapy and Biochemotherapy for Melanoma

  • Chia-Yen Hung
  • John Wen-Cheng Chang
Chapter

Abstract

The incidence of melanoma is increasing around the world, with the majority of patients diagnosed with a localized disease. Surgical treatment remains the preferred treatment method for localized diseases. However, high-risk patients have been found to have a high risk of recurrence and distant metastasis, including stage IIB (depth > 4 mm) and stage III patients (subclinically or clinically positive regional lymph node involvement). For such patients, the recommendations are for adjuvant therapy, in order to decrease the likelihood of developing distant metastatic disease. Effective agents include high-dose interferon-alpha (IFNα), pegylated IFNα, and ipilimumab, all of which are FDA approved. Other options may include biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2 (IL-2) and IFNα. Several novel agents, including immune checkpoint inhibitors and targeted therapies, have significantly increased survival rates in unresectable, locally advanced and metastatic melanoma patients. Cytotoxic chemotherapy or immunotherapy with IL-2 or tumor necrosis factor-alpha (TNFα) have recently been utilized as salvage therapy for those patient unresponsive to other forms of treatment. However, (bio)chemotherapy still plays an important role in the adjuvant treatment for many patients with advanced melanoma.

Keywords

Melanoma Chemotherapy Biochemotherapy Immunotherapy Management 

References

  1. 1.
    Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009;27(1):3–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Sneyd M, Cox B. The control of melanoma in New Zealand. N Z Med J. 2006;119(1242):U2169.PubMedGoogle Scholar
  3. 3.
    Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684. J Clin Oncol. 1996;14(1):7–17.CrossRefPubMedGoogle Scholar
  5. 5.
    Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19(9):2370–80.CrossRefPubMedGoogle Scholar
  6. 6.
    Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18(12):2444–58.CrossRefPubMedGoogle Scholar
  7. 7.
    Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010;102(7):493–501.CrossRefPubMedGoogle Scholar
  8. 8.
    Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dreno B, et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer. 2008;112(5):982–94.CrossRefPubMedGoogle Scholar
  9. 9.
    Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012;30(31):3810–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Flaherty LE, Othus M, Atkins MB, Tuthill RJ, Thompson JA, Vetto JT, et al. Southwest oncology group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia group B, Children’s oncology group, eastern cooperative oncology group, and southwest oncology group. J Clin Oncol. 2014;32(33):3771–8.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–30.CrossRefPubMedGoogle Scholar
  12. 12.
    Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–55.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Surveillance E, and End Results Program (SEER). [cited 2017 02/23]. https://seer.cancer.gov/statfacts/html/melan.html.
  14. 14.
    O'Day SJ, Kim CJ, Reintgen DS. Metastatic melanoma: chemotherapy to biochemotherapy. Cancer Control. 2002;9:1.CrossRefGoogle Scholar
  15. 15.
    Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, Durant JR. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol. 1983;1(2):126–34.CrossRefPubMedGoogle Scholar
  16. 16.
    Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol. 1992;8(6):400–14.CrossRefPubMedGoogle Scholar
  17. 17.
    Lotze MT, Kirkwood JM. Cutaneous melanoma. In: DeVita Jr VT, Rosenberg SA, editors. DeVita, Hellman, Rosenberg’s cancer: principles & practice of oncology. 6th ed. Philadelphia: Lippincott, Williams & Wilkens; 2001. p. 2012–69.Google Scholar
  18. 18.
    Houghton AN, Legha S, Bajorin DF. In: Balch CM, Houghton AN, Milton CW, editors. Chemotherapy for metastatic melanoma. Philadelphia: JB Lippincott Company; 1992.Google Scholar
  19. 19.
    Atkins M. The role of cytotoxic chemotherapeutic agents either alone or in combination with biological response modifiers. New York: Marcel Dekker; 1997.Google Scholar
  20. 20.
    Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18(1):158–66.CrossRefPubMedGoogle Scholar
  21. 21.
    Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011;47(10):1476–83.CrossRefPubMedGoogle Scholar
  22. 22.
    Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22(6):1118–25.CrossRefPubMedGoogle Scholar
  23. 23.
    Glover D, Glick JH, Weiler C, Fox K, Guerry D. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol. 1987;5(4):574–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Hersh EM, O'Day SJ, Ribas A, Samlowski WE, Gordon MS, Shechter DE, et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 2010;116(1):155–63.PubMedGoogle Scholar
  25. 25.
    Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, et al. A randomized, controlled phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma. Annals of oncology : official journal of the European society for. Med Oncol. 2015;26(11):2267–74.Google Scholar
  26. 26.
    Quagliana JM, Stephens RL, Baker LH, Costanzi JJ. Vindesine in patients with metastatic malignant melanoma: a southwest oncology group study. J Clin Oncol. 1984;2(4):316–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17(9):2745–51.CrossRefPubMedGoogle Scholar
  28. 28.
    Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013;31(3):373–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009;27(17):2823–30.CrossRefPubMedGoogle Scholar
  30. 30.
    Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012;30(1):34–41.CrossRefPubMedGoogle Scholar
  31. 31.
    Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol. 1999;17(3):968–75.CrossRefPubMedGoogle Scholar
  32. 32.
    Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol. 2002;20(6):1600–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer melanoma group. J Clin Oncol. 2005;23(27):6747–55.CrossRefPubMedGoogle Scholar
  34. 34.
    Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002;20(8):2045–52.CrossRefPubMedGoogle Scholar
  35. 35.
    Sasse AD, Sasse EC, Clark LG, Ulloa L, Clark OA. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev. 2007;1:CD005413.Google Scholar
  36. 36.
    Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol. 2007;25(34):5426–34.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Hematology and Oncology Division, Internal Medicine DepartmentMackay Memorial Hospital, TaipeiNew TaipeiTaiwan
  2. 2.Division of Hematology and Oncology, Department of Internal MedicineChang Gung Memorial Hospital at Linkou, TaoyuanTaoyuanTaiwan

Personalised recommendations